Johns Hopkins IRB Approves Advancement of CMND-100 Clinical Trial to Next Stages
CMND sits 17% above its 52-week low of $2.1 on light trading volume (0.2× avg).
Summary
Clearmind Medicine received approval from Johns Hopkins IRB to advance its CMND-100 Phase I/II clinical trial for Alcohol Use Disorder to Parts B and C, marking a significant step in its drug development.
Key Events · Product Development and Regulatory · CMND
-
IRB Approval for CMND-100 Trial Advancement
The Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for Clearmind Medicine to advance its ongoing Phase I/II clinical trial of CMND-100.
-
Progression to Parts B and C
This approval permits the company to proceed with Parts B and C of the multi-center study, which is evaluating CMND-100 in healthy volunteers and Alcohol Use Disorder (AUD) subjects.
-
Significant Clinical Development Milestone
This milestone follows the successful completion of earlier trial stages and represents an important step forward in the clinical development program for CMND-100, a non-hallucinogenic MEAI-based candidate for AUD.
Analysis · CMND · Life Sciences
This approval from Johns Hopkins IRB to advance the CMND-100 Phase I/II clinical trial to Parts B and C is a significant de-risking event for Clearmind Medicine. For a clinical-stage biotech company, successful progression through trial phases is critical, validating the drug candidate's safety and tolerability and moving it closer to potential commercialization. This positive clinical development follows a recent 1-for-10 reverse stock split on May 21, 2026, and a series of convertible note issuances, suggesting the company is actively working to strengthen its position and advance its pipeline.
At the time of this filing, CMND was trading at $2.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $2.10 to $524.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.